Granulocyte macrophage colony-stimulating factor (GM-CSF) reduces pancytopenia after rescue therapy in a patient with hodgkin's lymphoma

Wanda Piacibello, Clara Camaschella, Angelika C. Stern, Massimo Aglietta

Research output: Contribution to journalArticle

Abstract

After several relapses, a stage IV lymphocyte depletion Hodgkin Lymphoma patient, with a bone marrow progenitor compartment depleted by several courses of chemotherapy, received further combination chemotherapy which caused severe and long-lasting pancytopenia. Because of an objective degree of tumor regression, a second identical course was administered, followed by Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in an attempt to accelerate bone marrow recovery. This led to a significantly shorter period of neutropenia and thrombocytopenia with no additional red blood cell and platelet transfusion requirements. Furthermore, the neutropenic phase was not accompanied by septic complications. It is suggested that patients with solid tumors, even with a severely compromised bone marrow after several chemotherapy courses, may benefit from GM-CSF administration after rescue chemotherapy.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalLeukemia and Lymphoma
Volume3
Issue number1
DOIs
Publication statusPublished - 1990

Fingerprint

Pancytopenia
Granulocyte-Macrophage Colony-Stimulating Factor
Hodgkin Disease
Bone Marrow
Drug Therapy
Erythrocyte Transfusion
Platelet Transfusion
Combination Drug Therapy
Neutropenia
Thrombocytopenia
Neoplasms
Therapeutics
Recurrence

Keywords

  • Chemotherapy
  • GM-CSF
  • Lymphoma
  • Pancytopenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{babf78e9786f42a48c57e515626b783a,
title = "Granulocyte macrophage colony-stimulating factor (GM-CSF) reduces pancytopenia after rescue therapy in a patient with hodgkin's lymphoma",
abstract = "After several relapses, a stage IV lymphocyte depletion Hodgkin Lymphoma patient, with a bone marrow progenitor compartment depleted by several courses of chemotherapy, received further combination chemotherapy which caused severe and long-lasting pancytopenia. Because of an objective degree of tumor regression, a second identical course was administered, followed by Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in an attempt to accelerate bone marrow recovery. This led to a significantly shorter period of neutropenia and thrombocytopenia with no additional red blood cell and platelet transfusion requirements. Furthermore, the neutropenic phase was not accompanied by septic complications. It is suggested that patients with solid tumors, even with a severely compromised bone marrow after several chemotherapy courses, may benefit from GM-CSF administration after rescue chemotherapy.",
keywords = "Chemotherapy, GM-CSF, Lymphoma, Pancytopenia",
author = "Wanda Piacibello and Clara Camaschella and Stern, {Angelika C.} and Massimo Aglietta",
year = "1990",
doi = "10.3109/10428199009050976",
language = "English",
volume = "3",
pages = "61--66",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Granulocyte macrophage colony-stimulating factor (GM-CSF) reduces pancytopenia after rescue therapy in a patient with hodgkin's lymphoma

AU - Piacibello, Wanda

AU - Camaschella, Clara

AU - Stern, Angelika C.

AU - Aglietta, Massimo

PY - 1990

Y1 - 1990

N2 - After several relapses, a stage IV lymphocyte depletion Hodgkin Lymphoma patient, with a bone marrow progenitor compartment depleted by several courses of chemotherapy, received further combination chemotherapy which caused severe and long-lasting pancytopenia. Because of an objective degree of tumor regression, a second identical course was administered, followed by Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in an attempt to accelerate bone marrow recovery. This led to a significantly shorter period of neutropenia and thrombocytopenia with no additional red blood cell and platelet transfusion requirements. Furthermore, the neutropenic phase was not accompanied by septic complications. It is suggested that patients with solid tumors, even with a severely compromised bone marrow after several chemotherapy courses, may benefit from GM-CSF administration after rescue chemotherapy.

AB - After several relapses, a stage IV lymphocyte depletion Hodgkin Lymphoma patient, with a bone marrow progenitor compartment depleted by several courses of chemotherapy, received further combination chemotherapy which caused severe and long-lasting pancytopenia. Because of an objective degree of tumor regression, a second identical course was administered, followed by Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in an attempt to accelerate bone marrow recovery. This led to a significantly shorter period of neutropenia and thrombocytopenia with no additional red blood cell and platelet transfusion requirements. Furthermore, the neutropenic phase was not accompanied by septic complications. It is suggested that patients with solid tumors, even with a severely compromised bone marrow after several chemotherapy courses, may benefit from GM-CSF administration after rescue chemotherapy.

KW - Chemotherapy

KW - GM-CSF

KW - Lymphoma

KW - Pancytopenia

UR - http://www.scopus.com/inward/record.url?scp=0025552763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025552763&partnerID=8YFLogxK

U2 - 10.3109/10428199009050976

DO - 10.3109/10428199009050976

M3 - Article

AN - SCOPUS:0025552763

VL - 3

SP - 61

EP - 66

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -